One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Unfolding the worldwide incidence of bullous pemphigoid: what are we missing?
V. Aoki, D. Miyamoto
doi : 10.1111/bjd.20838
Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications
G. Dobos, C. Assaf
doi : 10.1111/bjd.20895
Targeting the neonatal Fc receptor in pemphigus: safety first
G. Micevic, S.N. Lo, N. Rajan
doi : 10.1111/bjd.20939
Postinflammatory hyperpigmentation and erythema: new insights into the pathogenesis
J.S.S. Concha, M. Afarideh, V.P. Werth
doi : 10.1111/bjd.20938
Ocular conjunctivitis in biological therapies for atopic dermatitis
R. Nguyen
doi : 10.1111/bjd.20945
Working towards a better understanding of VEXAS syndrome
L.T. Nicholson, L.M. Madigan
doi : 10.1111/bjd.20949
From FOS fusions to somatic mutations in the MAPK pathway, heterogeneous genetic abnormalities cause distinct pathophysiology among subsets of epithelioid haemangiomas
W. Tan, J.S. Nelson
doi : 10.1111/bjd.20952
Safety in numbers: risankizumab for moderate-to-severe psoriasis
S. Mirali, K. Fabusiwa, E. Linos
doi : 10.1111/bjd.20947
Questionnaire use depends on the study goal, target group and phase of the condition
A. Evers
doi : 10.1111/bjd.20948
Easy assessment tool for disease severity of atopic dermatitis in clinical practice
M. Futamura
doi : 10.1111/bjd.20951
British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021*
R.A. Sabroe, F. Lawlor, C.E.H. Grattan, M.R. Ardern-Jones, A. Bewley, L. Campbell, C. Flohr, T.A. Leslie, A.M. Marsland, G. Ogg, W.A.C. Sewell, M. Hashme, L.S. Exton, M.F. Mohd Mustapa, M.C. Ezejimofor, on behalf of the British Association of Dermatologists’ Clinical Standards Unit
doi : 10.1111/bjd.20892
The global incidence of bullous pemphigoid: a systematic review and meta-analysis
M.S.M. Persson, N. Begum, M.J. Grainge, K.E. Harman, D. Grindlay, S. Gran
doi : 10.1111/bjd.20743
National Institute for Health and Care Excellence (NICE) acne guideline: what’s the latest for dermatologists?
A.M. Layton, B.S. McDonald, M.F. Mohd Mustapa, N.J. Levell
doi : 10.1111/bjd.20888
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial*
M. Goebeler, Z. Bata-Csörgő, C. De Simone, B. Didona, E. Remenyik, N. Reznichenko, J. Stoevesandt, E.S. Ward, W. Parys, H. de Haard, P. Dupuy, P. Verheesen, E. Schmidt, P. Joly, the ARGX-113-1701 Investigator Study Group
doi : 10.1111/bjd.20782
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)*
J. Gutermuth, A.E. Pink, M. Worm, L. Soldbro, C. Bjerregård Øland, S. Weidinger
doi : 10.1111/bjd.20832
Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials
A. Wollenberg, L.A. Beck, M. de Bruin Weller, E.L. Simpson, S. Imafuku, M. Boguniewicz, R. Zachariae, C.K. Olsen, J.P. Thyssen
doi : 10.1111/bjd.20810
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis*
K.B. Gordon, M. Lebwohl, K.A. Papp, H. Bachelez, J.J. Wu, R.G. Langley, A. Blauvelt, B. Kaplan, M. Shah, Y. Zhao, R. Sinvhal, K. Reich
doi : 10.1111/bjd.20818
A nationwide study of the incidence and trends of first and multiple basal cell carcinomas in the Netherlands and prediction of future incidence*
K. Schreuder, L. Hollestein, T.E.C. Nijsten, M. Wakkee, M.W.J. Louwman
doi : 10.1111/bjd.20871
A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI-Relevant and Skindex-16*
�. Szabó, V. Brodszky, F. Rencz
doi : 10.1111/bjd.20765
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis*
A.S. Paller, J.K.L. Tan, J. Bagel, A.B. Rossi, B. Shumel, H. Zhang, A. Abramova
doi : 10.1111/bjd.20872
An in vivo model of postinflammatory hyperpigmentation and erythema: clinical, colorimetric and molecular characteristics*
G. Vellaichamy, I. Kohli, R. Zubair, C. Yin, T. Braunberger, A.F. Nahhas, C. Nicholson, T.F. Mohammad, P. Isedeh, A.B. Lyons, N. Nartker, M. Al-Jamal, M. Matsui, N. Karaman-Jurukovska, L. Zhou, H.W. Lim, Q.-S. Mi, I.H. Hamzavi
doi : 10.1111/bjd.20804
Transcriptomic changes during stage progression of mycosis fungoides
M.Z.X. Xiao, D. Hennessey, A. Iyer, S. O’Keefe, F. Zhang, A. Sivanand, R. Gniadecki
doi : 10.1111/bjd.20760
The mucin protein MUCL1 regulates melanogenesis and melanoma genes in a manner dependent on threonine content*
J. Kim, H. Choi
doi : 10.1111/bjd.20761
Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy*
A. Hoyer, E.M. Rehbinder, M. Färdig, S. Asad, K.C. Lødrup Carlsen, K.M.A. Endre, B. Granum, G. Haugen, G. Hedlin, C. Monceyron Jonassen, S. Katayama, J.R. Konradsen, L. Landrø, M. LeBlanc, C.A. Olsson Mägi, K. Rudi, H.O. Skjerven, A.C. Staff, R. Vettukattil, M. Bradley, B. Nordlund, C. Söderhäll
doi : 10.1111/bjd.20831
Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway
K. Maurus, C. Kosnopfel, H. Kneitz, S. Appenzeller, D. Schrama, V. Glutsch, S. Roth, E. Gerhard-Hartmann, M. Rosenfeldt, L. Möhrmann, M. Fröhlich, D. Hübschmann, A. Stenzinger, H. Glimm, S. Fröhling, M. Goebeler, A. Rosenwald, H. Kutzner, B. Schilling
doi : 10.1111/bjd.20869
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients*
S. Georgin-Lavialle, B. Terrier, A.F. Guedon, M. Heiblig, T. Comont, E. Lazaro, V. Lacombe, L. Terriou, S. Ardois, J.-D. Bouaziz, A. Mathian, G. Le Guenno, A. Aouba, R. Outh, A. Meyer, M. Roux-Sauvat, M. Ebbo, L.P. Zhao, A. Bigot, Y. Jamilloux, V. Guillotin, E. Flamarion, P. Henneton, G. Vial, V. Jachiet, J. Rossignol, S. Vinzio, T. Weitten, J. Vinit, C. Deligny, S. Humbert, M. Samson, N. Magy-Bertrand, T. Moulinet, R. Bourguiba, T. Hanslik, C. Bachmeyer, M. Sebert, M. Kostine, B. Bienvenu, P. Biscay, E. Liozon, L. Sailler, F. Chasset, A. Audemard-Verger, E. Duroyon, G. Sarrabay, F. Borlot, C. Dieval, T. Cluzeau, P. Marianetti, H. Lobbes, G. Boursier, M. Gerfaud-Valentin, J. Jeannel, A. Servettaz, S. Audia, M. Larue, B. Henriot, B. Faucher, J. Graveleau, B. de Sainte Marie, J. Galland, L. Bouillet, C. Arnaud, L. Ades, F. Carrat, P. Hirsch, P. Fenaux, O. Fain, P. Sujobert, O. Kosmider, A. Mekinian, French VEXAS group, on behalf of the GFEV, GFM, CEREMAIA, MINHEMON
doi : 10.1111/bjd.20805
Targeting the opioid pathway for the treatment of chronic kidney disease-associated pruritus: a systematic review and meta-analysis of randomized controlled trials
A.M.J. Bailey, H.O.-Y. Li, K. Burns, W. Cheng, D. Collister, E.P. Westby, K.S. Purdy, M. Walsh, K.K. Tennankore
doi : 10.1111/bjd.20769
A randomized assessor-blinded comparison of low-irradiance and conventional-irradiance photodynamic therapy for superficial basal cell carcinoma and Bowen disease
S.H. Ibbotson, J. Ferguson, H. Moseley, I.D.W. Samuel, A. Lesar, R.S. Dawe
doi : 10.1111/bjd.20762
Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors
P. Monnet, F. Herms, M. Djermane, S. Dalac, O. Dereure, B. Dréno, M. Beylot-Barry, L. Mortier, N. Basset-Seguin
doi : 10.1111/bjd.20808
Ultralow-dose rituximab in pemphigus: a single-centre experience
K. Simpson, Z.M. Low, T. Yap, J.S. Kern, L. Scardamaglia
doi : 10.1111/bjd.20819
Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes
M. Goldenberg, M. Amigo, S.G. Krishna, N. Milani-Nejad, J.C. Trinidad, B.H. Kaffenberger
doi : 10.1111/bjd.20868
Eltrombopag-associated erythromelalgia in idiopathic thrombocytopenic purpura
J. Perez, C. Khouri, S. Park, B. Imbert, J.-L. Cracowski
doi : 10.1111/bjd.20829
Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma
T. Maeda, A. Hiura, J. Uehara, R. Toyoshima, T. Nakagawa, K. Yoshino
doi : 10.1111/bjd.20879
Perineal cutaneous basal cell carcinomas in patients with familial seronegative coeliac disease: report of three cases
W.C. Lambert, C.B. Sy, A.P. Madari, R.A. Schwartz
doi : 10.1111/bjd.20870
Optimizing shared decision making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic
M.E.C. van Winden, F.M. Klösters, M. Hamaker, M.G. Olde Rikkert, P.C.M. van de Kerkhof, E.M.G.J. de Jong, S.F.K. Lubeek
doi : 10.1111/bjd.20833
Response to ‘A clinical and biological review of keratoacanthoma’: reply from authors
A. Tisack, A. Fotouhi, C. Fidai, B.J. Friedman, D. Ozog, J. Veenstra
doi : 10.1111/bjd.20835
Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine
T. Žagar, N. Hla�a, I. Brajac, L. Prpić-Massari, S. Peternel, M. Kaštelan
doi : 10.1111/bjd.20876
A comparison of the different questionnaires used to measure health-related quality of life in patients with dermatological conditions
doi : 10.1111/bjd.20985
Injectable tralokinumab gives new hope to patients with severe atopic dermatitis
doi : 10.1111/bjd.20986
Safety of long-term treatment with risankizumab in patients with moderate-to-severe plaque psoriasis
doi : 10.1111/bjd.20992
Insight into the number of patients diagnosed with basal cell carcinoma in the Netherlands and an estimation of future numbers
doi : 10.1111/bjd.20994
British Association of Dermatologists guidelines for the management of people with chronic urticaria
doi : 10.1111/bjd.20995
ä¸é‡�度斑å�—型银屑病患者长期使用瑞莎ç� å�•æŠ—治疗的安全性
doi : 10.1111/bjd.21003
深入了解è�·å…°è¯Šæ–为基底细胞癌的患者数é‡�以å�Šå¯¹æœªæ�¥æ‚£è€…æ•°é‡�的估计
doi : 10.1111/bjd.21005
